AstraZeneca's Imfinzi shows positive response in gastric cancers
peterschreiber.media
- Top-level phase 3 data on AstraZeneca's Imfinzi (durvalumab) showed statistically significant improvement in pathologic complete response compared to neoadjuvant chemotherapy alone in gastric and gastroesophageal junction cancers.
- The MATTERHORN trial is continuing to determine event-free survival and overall survival.
- In the trial, Imfinzi was added to standard-of-care chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) before surgery.